Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBAJ-876 DDI Study in Healthy Adults
NCT05526911Phase 1Completed
- Sponsor
- TB Alliance
- Start
- Jun 2022
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
Phase 1, open-label trial of TBAJ-876 in Tuberculosis (TB), sponsored by TB Alliance. Primary endpoint: Area Under the Curve of Midazolam at Day 20. Started Jun 2022; status: completed.
02
Drugs
TBAJ-876
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05526911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05526911.